1-3 of 3
Dezheng Huo, PhD
Close
Sort by
Journal Articles

High Dose Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction Therapy for High-Risk Acute Myeloid Leukemia (AML).

Sarah Larson, MD, Nicholas Campbell, MD, Dezheng Huo, PhD, Andrew Artz, MD, MS, Yanming Zhang, Devika Gajria, Margaret Green, Gamar Rahimova, Howard Weiner, Monica Torres, Olatoyosi Odenike, MD, Lucy A Godley, MD, PhD, Elizabeth Shima Rich, MD, PhD, Michael Thirman, MD, Richard A. Larson, MD, Wendy Stock, MD
Journal: Blood
Blood (2009) 114 (22): 1048.
https://doi.org/10.1182/blood.V114.22.1048.1048
Published: 2009
Journal Articles

Genomic Rearrangements Associated with -5/del(5q) and -7/del(7q) in Myeloid Leukemias.

Thelma R. Tennant, PhD, Dezheng Huo, PhD, Elizabeth M. Davis, Richard A. Larson, MD, Michelle M. Le Beau, PhD
Journal: Blood
Blood (2007) 110 (11): 1813.
https://doi.org/10.1182/blood.V110.11.1813.1813
Published: 2007
Journal Articles

New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).

Daniel A. Pollyea, MD, Andrew S. Artz, MD, Wendy Stock, MD, Christopher Daugherty, MD, Lucy Godley, MD PhD, Olatoyosi M. Odenike, MD, Elizabeth Rich, MD PhD, Sonali M. Smith, MD, Todd Zimmerman, MD, Yanming Zhang, PhD, Dezheng Huo, PhD, Richard Larson, MD, Koen Van Besien, MD
Journal: Blood
Blood (2006) 108 (11): 3675.
https://doi.org/10.1182/blood.V108.11.3675.3675
Published: 2006